

---

By: **Delegates Stern, Goldwater, Barve, Jones, Conway, McIntosh, Hixson, D. Davis, Rosenberg, Simmons, Elliott, Weldon, Barkley, Benson, Bronrott, Cane, V. Clagett, Cryor, Donoghue, Doory, Dumais, Feldman, Franchot, Frush, Glassman, Heller, Hubbard, James, King, Kullen, Lawton, Lee, Madaleno, Malone, Mandel, Marriott, McKee, Menes, Montgomery, Morhaim, Murray, Nathan-Pulliam, Oaks, Shank, Smigiel, Sossi, Stull, F. Turner, and V. Turner**

Introduced and read first time: February 10, 2006

Assigned to: Health and Government Operations

---

A BILL ENTITLED

1 AN ACT concerning

2 **Prescription Drug Safety Act**

3 FOR the purpose of requiring a wholesale distributor of prescription drugs to hold a  
4 license issued by the State Board of Pharmacy before the wholesale distributor  
5 engages in the wholesale distribution of prescription drugs in the State;  
6 requiring a nonresident wholesale distributor to hold certain licenses before the  
7 nonresident wholesale distributor engages in the wholesale distribution of  
8 prescription drugs; authorizing the Board to exempt from certain requirements  
9 a wholesale distributor accredited by a certain accreditation program;  
10 authorizing the Board to exempt a U.S. Food and Drug Administration licensed  
11 drug manufacturer from licensing requirements under certain circumstances;  
12 requiring an applicant for a license to meet certain requirements; requiring an  
13 application for a license to include certain items; requiring information on an  
14 application to be provided under oath; requiring an applicant to receive a certain  
15 inspection certificate; establishing requirements for an inspection certificate;  
16 authorizing the Board or a certain accreditation program to conduct an  
17 inspection at certain times and in a certain manner; authorizing the Board or a  
18 certain accreditation program to charge and collect fees for inspection activities;  
19 authorizing the Board to charge a fee, including a certain cost, to apply for or  
20 renew a license; requiring an applicant to submit a bond in a certain amount, or  
21 certain other equivalent means of security; authorizing the Board to waive the  
22 bond requirement under certain circumstances; requiring the Board to waive  
23 the bond requirement under certain circumstances; requiring the Board to  
24 establish a certain account; requiring the Board to apply to the Central  
25 Repository for certain criminal history records checks; establishing  
26 requirements for the criminal history records checks; authorizing the Board to  
27 conduct a financial background check; requiring the Board to issue a wholesale  
28 distributor license to an applicant that meets certain requirements; requiring  
29 the Board to give certain written notice, if the Board denies a license;

1 prohibiting the Board from issuing a license, unless the Board makes certain  
2 determinations; establishing the duration for a license; providing for the  
3 renewal of a license, under certain conditions; requiring the Board to establish  
4 certain continuing education requirements; authorizing the Board to take  
5 certain actions against a license of a wholesale distributor that commits certain  
6 violations; requiring a manufacturer located in the State to hold a license issued  
7 by the Board before the manufacturer invoices or ships prescription drugs in the  
8 State; requiring a nonresident manufacturer to hold a license before the  
9 nonresident manufacturer invoices or ships prescription drugs into the State;  
10 requiring an applicant for a manufacturer license to meet certain requirements;  
11 requiring an application for a license to include certain items and be certified by  
12 a notary public; requiring the Board to issue a manufacturer license to an  
13 applicant that meets certain requirements; requiring the Board to give certain  
14 written notice, if the Board denies a license; providing for the duration of a  
15 manufacturer license; providing for the renewal of a license under certain  
16 conditions; prohibiting the disclosure of certain information; providing for  
17 certain exceptions; requiring the Board to adopt regulations defining a certain  
18 emergency situation; requiring the Board to make a certain determination and  
19 take certain action, under certain circumstances; establishing requirements for  
20 prescription drug returns and exchanges; establishing certain due diligence  
21 requirements; establishing requirements for a wholesale distributor to supply  
22 and deliver prescription drugs; establishing requirements for payment and  
23 purchasing of prescription drugs; providing an exception for standard ordering  
24 and purchasing business practices; requiring a wholesale distributor to  
25 establish and maintain certain inventories and records regarding receipt and  
26 distribution or other disposition of prescription drugs; establishing pedigree  
27 requirements for the wholesale distribution of prescription drugs; requiring the  
28 Board to conduct a study of electronic pedigrees and other advanced tracking  
29 technology; authorizing the Board to mandate electronic pedigrees or other  
30 advanced tracking technology; requiring the Board to report the findings and  
31 recommendations of its study to the General Assembly on or before a certain  
32 date and adopt certain regulations within a certain time period; exempting a  
33 pharmacy benefits entity from the pedigree requirements, under certain  
34 circumstances; authorizing the Board to recognize certain laws and regulations  
35 as satisfying certain pedigree requirements; requiring the Board to issue an  
36 order to cease distribution of a prescription drug under certain circumstances;  
37 providing an opportunity for a certain hearing; authorizing the Board to vacate  
38 the order under certain circumstances; making it unlawful for a person to  
39 perform or cause to be performed or aid and abet certain acts; providing that it  
40 is not unlawful for a certain person to obtain or attempt to obtain a prescription  
41 drug for certain testing purposes; providing for certain penalties; defining  
42 certain terms; repealing certain provisions of law; and generally relating to  
43 prescription drug safety and requirements for the wholesale distribution of  
44 prescription drugs.

45 BY repealing  
46 Article - Health Occupations  
47 Section 12-602

1 Annotated Code of Maryland  
2 (2005 Replacement Volume)

3 BY adding to  
4 Article - Health Occupations  
5 Section 12-6B-01 through 12-6B-20, inclusive, to be under the new subtitle  
6 "Subtitle 6B. Prescription Drug Safety Act"  
7 Annotated Code of Maryland  
8 (2005 Replacement Volume)

9 BY repealing and reenacting, with amendments,  
10 Article - Health Occupations  
11 Section 12-707(b)  
12 Annotated Code of Maryland  
13 (2005 Replacement Volume)

14 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF  
15 MARYLAND, That Section(s) 12-602 of Article - Health Occupations of the  
16 Annotated Code of Maryland be repealed.

17 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland  
18 read as follows:

19 **Article - Health Occupations**

20 **SUBTITLE 6B. PRESCRIPTION DRUG SAFETY ACT.**

21 12-6B-01.

22 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS  
23 INDICATED.

24 (B) "CHAIN PHARMACY WAREHOUSE" MEANS A PHYSICAL LOCATION FOR  
25 PRESCRIPTION DRUGS THAT ACTS, IN PART OR IN WHOLE, AS A CENTRAL  
26 WAREHOUSE AND PERFORMS INTRACOMPANY SALES OR TRANSFERS OF THE  
27 PRESCRIPTION DRUGS TO A GROUP OF CHAIN PHARMACIES OR OTHER CHAIN  
28 PHARMACY WAREHOUSES THAT ARE UNDER COMMON OWNERSHIP OR CONTROL.

29 (C) "FACILITY" MEANS A FACILITY OF A WHOLESALE DISTRIBUTOR IN WHICH  
30 PRESCRIPTION DRUGS ARE STORED, HANDLED, REPACKAGED, OR OFFERED FOR  
31 SALE.

32 (D) (1) "MANUFACTURER" MEANS A PERSON THAT MANUFACTURES OR  
33 PACKAGES PRESCRIPTION DRUGS.

34 (2) "MANUFACTURER" INCLUDES:

35 (I) AN AFFILIATE;

1 (II) A SUBSIDIARY;

2 (III) AN AGENT;

3 (IV) ANOTHER ENTITY UNDER COMMON OWNERSHIP AND CONTROL  
4 WITH A MANUFACTURER.

5 (E) "NORMAL DISTRIBUTION CHANNEL" MEANS THE ROUTE THAT A  
6 PRESCRIPTION DRUG TRAVELS:

7 (1) FROM A MANUFACTURER TO A WHOLESALE DISTRIBUTOR, TO A  
8 PHARMACY, AND TO A CONSUMER;

9 (2) FROM A MANUFACTURER TO A WHOLESALE DISTRIBUTOR, TO A  
10 CHAIN PHARMACY WAREHOUSE, TO A PHARMACY AFFILIATED WITH THE CHAIN  
11 PHARMACY WAREHOUSE, AND TO A CONSUMER;

12 (3) FROM A MANUFACTURER TO A CHAIN PHARMACY WAREHOUSE, TO A  
13 PHARMACY AFFILIATED WITH THE CHAIN PHARMACY WAREHOUSE, AND TO A  
14 CONSUMER; OR

15 (4) AS PROVIDED IN REGULATIONS ADOPTED BY THE BOARD.

16 (F) "PEDIGREE" MEANS A DOCUMENT OR ELECTRONIC FILE CONTAINING  
17 INFORMATION THAT RECORDS EACH DISTRIBUTION OF ANY GIVEN PRESCRIPTION  
18 DRUG INSIDE OR OUTSIDE THE NORMAL DISTRIBUTION CHANNEL.

19 (G) "PHARMACY BENEFITS ENTITY" MEANS AN ENTITY THAT ASSISTS IN THE  
20 ADMINISTRATION OF PHARMACY BENEFITS:

21 (1) UNDER CONTRACTS WITH INSURERS; OR

22 (2) TO A COMPANY UNDER COMMON OWNERSHIP OR CONTROL WITH  
23 THE ENTITY.

24 (H) (1) "PRESCRIPTION DRUG" MEANS ANY DRUG REQUIRED BY FEDERAL  
25 LAW, FEDERAL REGULATION, OR STATE LAW TO BE DISPENSED ONLY BY A  
26 PRESCRIPTION.

27 (2) "PRESCRIPTION DRUG" INCLUDES:

28 (I) ANY BIOLOGICAL PRODUCT, EXCEPT:

29 1. BLOOD AND BLOOD COMPONENTS INTENDED FOR  
30 TRANSFUSION; OR

31 2. BIOLOGICAL PRODUCTS THAT ARE ALSO MEDICAL  
32 DEVICES;

33 (II) FINISHED DOSAGE FORMS; AND

1 (III) BULK DRUG SUBSTANCES SUBJECT TO SECTION 503(B) OF THE  
2 FEDERAL FOOD, DRUG, AND COSMETIC ACT.

3 (I) (1) "REPACKAGE" MEANS REPACKAGING OR OTHERWISE CHANGING THE  
4 CONTAINER, WRAPPER, OR LABELING TO FURTHER THE DISTRIBUTION OF A  
5 PRESCRIPTION DRUG.

6 (2) "REPACKAGE" DOES NOT INCLUDE REPACKAGING COMPLETED BY  
7 THE PHARMACIST WHO DISPENSES THE PRESCRIPTION DRUG TO THE CONSUMER.

8 (J) "REPACKAGER" MEANS A PERSON WHO REPACKAGES.

9 (K) "WHOLESALE DISTRIBUTOR" OR "WHOLESALE" MEANS A PERSON  
10 ENGAGED IN THE WHOLESALE DISTRIBUTION OF PRESCRIPTION DRUGS, INCLUDING:

11 (1) REPACKAGERS;

12 (2) OWN-LABEL DISTRIBUTORS;

13 (3) PRIVATE-LABEL DISTRIBUTORS;

14 (4) JOBBERS;

15 (5) BROKERS;

16 (6) WAREHOUSES, INCLUDING MANUFACTURERS' AND DISTRIBUTORS'  
17 WAREHOUSES;

18 (7) INDEPENDENT WHOLESALE DRUG TRADERS;

19 (8) RETAIL PHARMACIES THAT CONDUCT WHOLESALE DISTRIBUTION;  
20 AND

21 (9) CHAIN PHARMACY WAREHOUSES THAT CONDUCT WHOLESALE  
22 DISTRIBUTION.

23 (L) (1) "WHOLESALE DISTRIBUTION" MEANS DISTRIBUTION OF  
24 PRESCRIPTION DRUGS TO PERSONS OTHER THAN A CONSUMER.

25 (2) "WHOLESALE DISTRIBUTION" DOES NOT INCLUDE:

26 (I) INTRACOMPANY SALES OR TRANSFERS OF PRESCRIPTION  
27 DRUGS THAT INVOLVE A TRANSACTION OR TRANSFER BETWEEN ANY DIVISION,  
28 SUBSIDIARY, PARENT, OR AFFILIATED OR RELATED COMPANY UNDER COMMON  
29 OWNERSHIP AND CONTROL;

30 (II) THE SALE, PURCHASE, DISTRIBUTION, TRADE, OR TRANSFER OF  
31 A PRESCRIPTION DRUG OR OFFER TO SELL, PURCHASE, DISTRIBUTE, TRADE, OR  
32 TRANSFER A PRESCRIPTION DRUG IN:

1                                   1.       A CATASTROPHIC HEALTH EMERGENCY PROCLAIMED BY  
2 THE GOVERNOR UNDER § 14-3A-02 OF THE PUBLIC SAFETY ARTICLE; OR

3                                   2.       AN EMERGENCY SITUATION, AS DEFINED BY THE BOARD  
4 IN REGULATIONS;

5                                   (III)    THE DISTRIBUTION OF PRESCRIPTION DRUG SAMPLES TO  
6 AUTHORIZED PRESCRIBERS BY MANUFACTURERS' REPRESENTATIVES;

7                                   (IV)    DRUG RETURNS, WHEN CONDUCTED BY A HOSPITAL, HEALTH  
8 CARE ENTITY, OR CHARITABLE INSTITUTION IN ACCORDANCE WITH 21 C.F.R. § 203.23;

9                                   (V)     THE SALE OF MINIMAL QUANTITIES OF PRESCRIPTION DRUGS  
10 BY RETAIL PHARMACIES TO AUTHORIZED PRESCRIBERS FOR OFFICE USE;

11                                  (VI)    DELIVERY OF PRESCRIPTION DRUGS BY RETAIL PHARMACIES  
12 TO A CONSUMER PURSUANT TO A PRESCRIPTION;

13                                  (VII)   THE SALE, TRANSFER, MERGER, OR CONSOLIDATION OF ALL OR  
14 PART OF THE BUSINESS OF A PHARMACY OR PHARMACIES FROM OR WITH ANOTHER  
15 PHARMACY OR PHARMACIES, WHETHER ACCOMPLISHED AS A PURCHASE AND SALE  
16 OF STOCK OR BUSINESS ASSETS; OR

17                                  (VIII)  THE SALE OR TRANSFER FROM A RETAIL PHARMACY OR CHAIN  
18 PHARMACY WAREHOUSE OF EXPIRED, DAMAGED, RETURNED, OR RECALLED DRUGS  
19 TO THE ORIGINAL MANUFACTURER, WHOLESALER, OR THIRD PARTY RETURNS  
20 PROCESSOR.

21 12-6B-02.

22       BY REGULATION, THE BOARD MAY EXEMPT FROM ANY REQUIREMENT OF THIS  
23 SUBTITLE A WHOLESALE DISTRIBUTOR ACCREDITED BY A NATIONALLY  
24 RECOGNIZED ACCREDITATION ENTITY APPROVED BY THE BOARD.

25 12-6B-03.

26       (A)     A WHOLESALE DISTRIBUTOR SHALL HOLD A LICENSE ISSUED BY THE  
27 BOARD BEFORE THE WHOLESALE DISTRIBUTOR ENGAGES IN THE WHOLESALE  
28 DISTRIBUTION OF PRESCRIPTION DRUGS IN THE STATE.

29       (B)     BEFORE A NONRESIDENT WHOLESALE DISTRIBUTOR ENGAGES IN THE  
30 WHOLESALE DISTRIBUTION OF PRESCRIPTION DRUGS IN THE STATE, THE  
31 NONRESIDENT WHOLESALE DISTRIBUTOR SHALL BE LICENSED:

32                                  (1)     IN THE STATE IN WHICH THE NONRESIDENT WHOLESALE  
33 DISTRIBUTOR IS LOCATED; AND

34                                  (2)     IN EACH STATE IN WHICH THE NONRESIDENT WHOLESALE  
35 DISTRIBUTOR SHIPS PRESCRIPTION DRUGS.

1 (C) THE BOARD SHALL EXEMPT A FOOD AND DRUG ADMINISTRATION  
2 LICENSED DRUG MANUFACTURER INCLUDING ITS AFFILIATES, SUBSIDIARIES,  
3 AGENTS, AND OTHER ENTITIES UNDER COMMON OWNERSHIP AND CONTROL WITH  
4 THE MANUFACTURER, FROM THE LICENSING REQUIREMENTS OF THIS SECTION, IF  
5 THE MANUFACTURER, ITS AFFILIATES, SUBSIDIARIES, AGENTS, AND OTHER  
6 ENTITIES UNDER COMMON OWNERSHIP AND CONTROL WITH THE MANUFACTURER,  
7 SHIP OR INVOICE ONLY THE MANUFACTURER'S PRODUCT INTO THE STATE.

8 (D) TO OBTAIN A LICENSE, AN APPLICANT SHALL:

9 (1) SUBMIT AN APPLICATION TO THE BOARD ON THE FORM AND IN THE  
10 MANNER REQUIRED BY THE BOARD;

11 (2) PAY TO THE BOARD AN APPLICATION FEE, AS AUTHORIZED UNDER  
12 § 12-6B-05 OF THIS SUBTITLE;

13 (3) RECEIVE AN INSPECTION CERTIFICATE FROM OR APPROVED BY THE  
14 BOARD, AS REQUIRED UNDER § 12-6B-06 OF THIS SUBTITLE; AND

15 (4) POST THE BOND REQUIRED UNDER § 12-6B-07 OF THIS SUBTITLE.

16 12-6B-04.

17 (A) THE APPLICATION UNDER § 12-6B-03 OF THIS SUBTITLE SHALL INCLUDE:

18 (1) THE NAME, FULL BUSINESS ADDRESS, AND TELEPHONE NUMBER OF  
19 THE APPLICANT;

20 (2) ALL TRADE OR BUSINESS NAMES USED BY THE APPLICANT;

21 (3) ADDRESSES, TELEPHONE NUMBERS, AND THE NAMES OF  
22 DESIGNATED REPRESENTATIVES FOR ALL FACILITIES USED BY THE APPLICANT;

23 (4) THE TYPE OF OWNERSHIP OR OPERATION OF THE APPLICANT;

24 (5) THE NAMES OF THE OWNER AND OPERATOR OF THE APPLICANT,  
25 INCLUDING:

26 (I) IF AN INDIVIDUAL, THE NAME OF THE INDIVIDUAL;

27 (II) IF A PARTNERSHIP, THE NAME OF EACH PARTNER, AND THE  
28 NAME OF THE PARTNERSHIP;

29 (III) IF A CORPORATION, THE NAME AND TITLE OF EACH  
30 CORPORATE OFFICER AND DIRECTOR, THE CORPORATE NAMES, AND THE STATE OF  
31 INCORPORATION; AND

32 (IV) IF A SOLE PROPRIETORSHIP, THE FULL NAME OF THE SOLE  
33 PROPRIETOR AND THE NAME OF THE BUSINESS ENTITY;

1 (6) A LIST OF ALL LICENSES AND PERMITS ISSUED TO THE APPLICANT  
2 BY ANY OTHER STATE THAT AUTHORIZES THE APPLICANT TO PURCHASE OR POSSESS  
3 PRESCRIPTION DRUGS;

4 (7) INFORMATION REGARDING THE APPLICANT'S DESIGNATED  
5 REPRESENTATIVE FOR EACH FACILITY OPERATED BY THE APPLICANT IN THE STATE,  
6 INCLUDING:

7 (I) NAME;

8 (II) RESIDENCE ADDRESSES FOR THE PAST 7 YEARS;

9 (III) DATE AND PLACE OF BIRTH;

10 (IV) OCCUPATIONS, POSITIONS OF EMPLOYMENT, AND OFFICES  
11 HELD DURING THE PAST 7 YEARS;

12 (V) NAME AND ADDRESS OF EACH BUSINESS, CORPORATION, OR  
13 OTHER ORGANIZATION IN WHICH THE DESIGNATED REPRESENTATIVE WAS  
14 EMPLOYED, HELD OFFICE, AND CARRIED ON AN OCCUPATION;

15 (VI) WHETHER THE DESIGNATED REPRESENTATIVE HAS BEEN,  
16 DURING THE PAST 7 YEARS, THE SUBJECT OF ANY PROCEEDING FOR THE  
17 REVOCATION OF ANY LICENSE OR ANY CRIMINAL VIOLATION AND, IF SO, THE  
18 NATURE OF THE PROCEEDING AND THE DISPOSITION OF THE PROCEEDING;

19 (VII) 1. WHETHER, DURING THE PAST 7 YEARS, A COURT OF  
20 COMPETENT JURISDICTION HAS RESTRICTED THE ABILITY OF THE DESIGNATED  
21 REPRESENTATIVE TO POSSESS, CONTROL, OR DISTRIBUTE PRESCRIPTION DRUGS;  
22 AND

23 2. THE REASONS FOR ANY SUCH RESTRICTION;

24 (VIII) A DESCRIPTION OF:

25 1. ANY INVOLVEMENT, INCLUDING ANY INVESTMENTS,  
26 OTHER THAN THE OWNERSHIP OF STOCK IN A PUBLICLY TRADED COMPANY OR  
27 MUTUAL FUND, BY THE DESIGNATED REPRESENTATIVE DURING THE PAST 7 YEARS,  
28 WITH ANY BUSINESS THAT MANUFACTURED, ADMINISTERED, PRESCRIBED,  
29 DISTRIBUTED, OR STORED PHARMACEUTICAL PRODUCTS; AND

30 2. ANY LAWSUITS IN WHICH THE BUSINESSES WERE NAMED  
31 AS A PARTY; AND

32 (IX) A DESCRIPTION OF ANY MISDEMEANOR OR FELONY CRIMINAL  
33 OFFENSE OF WHICH THE AUTHORIZED REPRESENTATIVE, AS AN ADULT, WAS FOUND  
34 GUILTY, REGARDLESS OF WHETHER ADJUDICATION OF GUILT WAS WITHHELD OR  
35 WHETHER THE AUTHORIZED REPRESENTATIVE PLED GUILTY OR NOLO  
36 CONTENDERE;



1 (8) A PHOTOGRAPH OF THE DESIGNATED REPRESENTATIVE TAKEN IN  
2 THE PREVIOUS 30 DAYS; AND

3 (9) THE FINGERPRINTS REQUIRED UNDER § 12-6B-08 OF THIS SUBTITLE.

4 (B) IF THE APPLICATION INDICATES THAT THE DESIGNATED  
5 REPRESENTATIVE HAS A CRIMINAL CONVICTION THAT IS UNDER APPEAL:

6 (1) THE APPLICATION SHALL INCLUDE A COPY OF THE NOTICE OF  
7 APPEAL OF THAT CRIMINAL OFFENSE; AND

8 (2) THE APPLICANT SHALL SUBMIT, WITHIN 15 DAYS AFTER THE  
9 DISPOSITION OF THE APPEAL, A COPY OF THE FINAL WRITTEN ORDER OF  
10 DISPOSITION.

11 (C) THE INFORMATION REQUIRED UNDER THIS SECTION SHALL BE PROVIDED  
12 UNDER OATH.

13 12-6B-05.

14 (A) THE BOARD MAY CHARGE A FEE, AS PROVIDED IN REGULATION, TO APPLY  
15 FOR OR RENEW A LICENSE.

16 (B) THE FEE SHALL INCLUDE THE COST OF PROCESSING ANY CRIMINAL  
17 HISTORY RECORDS CHECK OR FINANCIAL BACKGROUND CHECK CONDUCTED BY OR  
18 THROUGH THE BOARD.

19 12-6B-06.

20 (A) AN APPLICANT SHALL RECEIVE AN INSPECTION CERTIFICATE FROM OR  
21 APPROVED BY THE BOARD FOR EACH FACILITY OPERATED BY THE APPLICANT IN  
22 THE STATE BEFORE THE BOARD MAY ISSUE A LICENSE TO THE APPLICANT.

23 (B) TO RECEIVE AN INSPECTION CERTIFICATE, AN APPLICANT SHALL PASS A  
24 PHYSICAL INSPECTION OF EACH FACILITY CONDUCTED BY:

25 (1) THE BOARD; OR

26 (2) A NATIONALLY RECOGNIZED ACCREDITATION PROGRAM  
27 DESIGNATED BY THE BOARD TO CONDUCT INSPECTIONS ON THE BOARD'S BEHALF.

28 (C) AN INSPECTION CERTIFICATE SHALL BE VALID FOR NO MORE THAN 3  
29 YEARS.

30 (D) THE BOARD OR A NATIONALLY RECOGNIZED ACCREDITATION PROGRAM  
31 DESIGNATED BY THE BOARD TO CONDUCT INSPECTIONS ON THE BOARD'S BEHALF  
32 MAY CONDUCT AN INSPECTION OF A FACILITY OF A WHOLESALE DISTRIBUTOR IN  
33 THE MANNER AND AT THE TIMES PROVIDED IN REGULATIONS ADOPTED BY THE  
34 BOARD.

1 (E) AS PART OF AN INSPECTION, THE BOARD MAY REQUIRE PRESCRIPTION  
2 DRUGS AT THE FACILITY BE ANALYZED TO VERIFY THE AUTHENTICITY OF THE  
3 PRESCRIPTION DRUGS.

4 (F) THE BOARD OR A NATIONALLY RECOGNIZED ACCREDITATION PROGRAM  
5 DESIGNATED BY THE BOARD TO CONDUCT INSPECTIONS ON THE BOARD'S BEHALF  
6 MAY CHARGE AND COLLECT FEES FOR INSPECTION ACTIVITIES CONDUCTED UNDER  
7 THIS SECTION.

8 12-6B-07.

9 (A) THE BOARD SHALL REQUIRE EACH WHOLESALE DISTRIBUTOR APPLYING  
10 FOR A LICENSE TO SUBMIT A BOND OF AT LEAST \$100,000, OR OTHER EQUIVALENT  
11 MEANS OF SECURITY ACCEPTABLE TO THE BOARD, SUCH AS AN IRREVOCABLE  
12 LETTER OF CREDIT OR A DEPOSIT IN A TRUST ACCOUNT OR FINANCIAL INSTITUTION,  
13 PAYABLE TO AN ACCOUNT ESTABLISHED BY THE BOARD IN ACCORDANCE WITH  
14 SUBSECTION (F) OF THIS SECTION.

15 (B) THE PURPOSE OF THE BOND IS TO SECURE PAYMENT OF ANY FINES OR  
16 PENALTIES IMPOSED BY THE BOARD AND ANY FEES AND COSTS INCURRED BY THE  
17 BOARD REGARDING A LICENSE, THAT THE LICENSEE FAILS TO PAY WITHIN 30 DAYS  
18 AFTER THE FINES, PENALTIES, OR COSTS BECOME FINAL.

19 (C) (1) THE BOARD MAY WAIVE THE BOND REQUIREMENT IF THE  
20 WHOLESALE DISTRIBUTOR HAS IN PLACE A COMPARABLE BOND OR OTHER  
21 EQUIVALENT MEANS OF SECURITY FOR THE PURPOSE STATED IN SUBSECTION (B) OF  
22 THIS SECTION IN ANOTHER STATE IN WHICH THE WHOLESALE DISTRIBUTOR  
23 POSSESSES A WHOLESALE DISTRIBUTOR LICENSE IN GOOD STANDING.

24 (2) THE BOARD SHALL WAIVE THE BOND REQUIREMENT IF THE  
25 WHOLESALE DISTRIBUTOR IS UNDER COMMON OWNERSHIP OR CONTROL WITH AN  
26 ENTITY THAT HAS BEEN LICENSED BY THE BOARD.

27 (D) THE STATE MAY MAKE A CLAIM AGAINST THE BOND OR SECURITY  
28 SUBMITTED BY A WHOLESALE DISTRIBUTOR UNTIL 1 YEAR AFTER THE WHOLESALE  
29 DISTRIBUTOR'S LICENSE CEASES TO BE VALID.

30 (E) THE BOND SHALL COVER ALL FACILITIES OPERATED BY THE APPLICANT  
31 IN THE STATE.

32 (F) THE BOARD SHALL ESTABLISH AN ACCOUNT, SEPARATE FROM ITS OTHER  
33 ACCOUNTS, IN WHICH TO DEPOSIT ANY FUNDS RECEIVED FROM THE BOND OR  
34 SECURITY OF A WHOLESALE DISTRIBUTOR.

35 12-6B-08.

36 (A) THE BOARD SHALL APPLY TO THE CENTRAL REPOSITORY FOR A STATE  
37 AND NATIONAL CRIMINAL HISTORY RECORDS CHECK FOR EACH DESIGNATED  
38 REPRESENTATIVE OF AN APPLICANT, AS INDICATED ON THE APPLICATION FOR A  
39 LICENSE.

1 (B) (1) AS PART OF THE APPLICATION FOR A CRIMINAL HISTORY RECORDS  
2 CHECK, THE BOARD SHALL SUBMIT TO THE CENTRAL REPOSITORY:

3 (I) TWO COMPLETE SETS OF THE DESIGNATED REPRESENTATIVE'S  
4 LEGIBLE FINGERPRINTS TAKEN ON FORMS APPROVED BY THE DIRECTOR OF THE  
5 CENTRAL REPOSITORY AND THE DIRECTOR OF THE FEDERAL BUREAU OF  
6 INVESTIGATION;

7 (II) THE FEE AUTHORIZED IN § 10-221(B)(7) OF THE CRIMINAL  
8 PROCEDURE ARTICLE FOR ACCESS TO MARYLAND CRIMINAL HISTORY RECORDS; AND

9 (III) THE MANDATORY PROCESSING FEE REQUIRED BY THE  
10 FEDERAL BUREAU OF INVESTIGATION FOR A NATIONAL CRIMINAL HISTORY  
11 RECORDS CHECK.

12 (2) IN ACCORDANCE WITH TITLE 10, SUBTITLE 2 OF THE CRIMINAL  
13 PROCEDURE ARTICLE, THE CENTRAL REPOSITORY SHALL FORWARD TO THE  
14 DESIGNATED REPRESENTATIVE AND THE BOARD A PRINTED STATEMENT OF THE  
15 DESIGNATED REPRESENTATIVE'S CRIMINAL HISTORY RECORD INFORMATION.

16 (3) THE SUBJECT OF A CRIMINAL HISTORY RECORDS CHECK UNDER  
17 THIS SUBSECTION MAY CONTEST THE CONTENTS OF THE PRINTED STATEMENT  
18 ISSUED BY THE CENTRAL REPOSITORY AS PROVIDED IN § 10-223 OF THE CRIMINAL  
19 PROCEDURE ARTICLE.

20 (C) THE BOARD MAY CONDUCT A FINANCIAL BACKGROUND CHECK ON A  
21 DESIGNATED REPRESENTATIVE OF AN APPLICANT.

22 12-6B-09.

23 (A) THE BOARD SHALL ISSUE A WHOLESALE DISTRIBUTOR LICENSE TO ANY  
24 APPLICANT THAT MEETS THE REQUIREMENTS OF THIS SUBTITLE.

25 (B) IF THE BOARD DENIES A WHOLESALE DISTRIBUTOR LICENSE TO AN  
26 APPLICANT, IT SHALL GIVE THE APPLICANT WRITTEN NOTICE OF ITS DECISION AND  
27 THE REASONS FOR THE DENIAL.

28 (C) THE BOARD MAY NOT ISSUE A WHOLESALE DISTRIBUTOR LICENSE TO AN  
29 APPLICANT, UNLESS THE BOARD DETERMINES THAT EACH DESIGNATED  
30 REPRESENTATIVE OF THE APPLICANT, AT MINIMUM:

31 (1) IS AT LEAST 21 YEARS OF AGE;

32 (2) HAS BEEN EMPLOYED FULL TIME FOR AT LEAST 3 YEARS IN A  
33 PHARMACY OR WITH A WHOLESALE DISTRIBUTOR IN A CAPACITY RELATED TO THE  
34 DISPENSING AND DISTRIBUTION OF, AND RECORD KEEPING RELATING TO,  
35 PRESCRIPTION DRUGS;

36 (3) IS EMPLOYED BY THE APPLICANT FULL TIME IN A MANAGERIAL  
37 LEVEL POSITION;

1 (4) IS ACTIVELY INVOLVED IN AND AWARE OF THE ACTUAL DAILY  
2 OPERATION OF THE WHOLESALE DISTRIBUTOR;

3 (5) IS PHYSICALLY PRESENT AT THE FACILITY OF THE APPLICANT  
4 DURING REGULAR BUSINESS HOURS, EXCEPT WHEN THE ABSENCE OF THE  
5 DESIGNATED REPRESENTATIVE IS AUTHORIZED, INCLUDING SICK LEAVE AND  
6 VACATION LEAVE;

7 (6) IS SERVING IN THE CAPACITY OF A DESIGNATED REPRESENTATIVE  
8 FOR ONLY ONE APPLICANT AT A TIME;

9 (7) DOES NOT HAVE ANY CONVICTIONS UNDER ANY FEDERAL, STATE,  
10 OR LOCAL LAWS RELATING TO WHOLESALE OR RETAIL PRESCRIPTION DRUG  
11 DISTRIBUTION OR DISTRIBUTION OF CONTROLLED SUBSTANCES; AND

12 (8) DOES NOT HAVE ANY FELONY CONVICTIONS UNDER FEDERAL,  
13 STATE, OR LOCAL LAWS.

14 12-6B-10.

15 (A) A WHOLESALE DISTRIBUTOR LICENSE SHALL BE VALID FOR A PERIOD OF 1  
16 YEAR.

17 (B) A LICENSE EXPIRES ON A DATE SET BY THE BOARD, UNLESS THE LICENSE  
18 IS RENEWED FOR AN ADDITIONAL 1-YEAR PERIOD AS PROVIDED IN THIS SECTION.

19 (C) AT LEAST 1 MONTH BEFORE THE LICENSE EXPIRES, THE BOARD SHALL  
20 PROVIDE TO THE LICENSEE A RENEWAL NOTICE THAT STATES:

21 (1) THE DATE ON WHICH THE CURRENT LICENSE EXPIRES;

22 (2) THE DATE BY WHICH THE RENEWAL APPLICATION MUST BE  
23 RECEIVED BY THE BOARD FOR THE RENEWAL TO BE PROCESSED BEFORE THE  
24 LICENSE EXPIRES; AND

25 (3) THE AMOUNT OF THE RENEWAL FEE.

26 (D) BEFORE THE LICENSE EXPIRES, THE LICENSEE MAY RENEW THE LICENSE  
27 FOR AN ADDITIONAL 1-YEAR PERIOD, IF THE LICENSEE:

28 (1) SUBMITS TO THE BOARD:

29 (I) A RENEWAL APPLICATION ON THE FORM THE BOARD  
30 REQUIRES; AND

31 (II) SATISFACTORY EVIDENCE OF COMPLIANCE WITH ANY  
32 CONTINUING EDUCATION AND OTHER QUALIFICATIONS AND REQUIREMENTS SET  
33 UNDER THIS SUBTITLE FOR LICENSE RENEWAL;

34 (2) HAS A CURRENT INSPECTION CERTIFICATE FOR EACH FACILITY  
35 OPERATED BY THE LICENSEE IN THE STATE; AND

1 (3) PAYS TO THE BOARD A RENEWAL FEE SET BY THE BOARD.

2 (E) THE RENEWAL APPLICATION SHALL REQUIRE THE LICENSEE TO UPDATE  
3 THE INFORMATION PROVIDED UNDER § 12-6B-04 OF THIS SUBTITLE.

4 (F) (1) THE BOARD SHALL ESTABLISH CONTINUING EDUCATION  
5 REQUIREMENTS FOR THE DESIGNATED REPRESENTATIVE IDENTIFIED IN  
6 ACCORDANCE WITH § 12-6B-04 OF THIS SUBTITLE.

7 (2) CONTINUING EDUCATION SHALL INCLUDE EDUCATION REGARDING  
8 FEDERAL AND STATE LAWS GOVERNING WHOLESALE DISTRIBUTION OF  
9 PRESCRIPTION DRUGS.

10 12-6B-11.

11 SUBJECT TO THE HEARING PROVISIONS OF § 12-315 OF THIS TITLE, THE BOARD  
12 MAY FINE, CENSURE, REPRIMAND, PLACE ON PROBATION, OR SUSPEND OR REVOKE  
13 THE LICENSE OF A WHOLESALE DISTRIBUTOR THAT VIOLATES ANY PROVISION OF  
14 THIS SUBTITLE.

15 12-6B-12.

16 (A) (1) A MANUFACTURER LOCATED IN THE STATE SHALL BE LICENSED BY  
17 THE BOARD BEFORE THE MANUFACTURER INVOICES OR SHIPS ITS OWN  
18 PRESCRIPTION DRUGS.

19 (2) A NONRESIDENT MANUFACTURER SHALL BE LICENSED BY THE  
20 BOARD BEFORE THE NONRESIDENT MANUFACTURER INVOICES OR SHIPS  
21 PRESCRIPTION DRUGS INTO THE STATE.

22 (B) TO OBTAIN A LICENSE UNDER THIS SECTION, A MANUFACTURER SHALL:

23 (1) SUBMIT AN APPLICATION TO THE BOARD ON THE FORM AND IN THE  
24 MANNER REQUIRED BY THE BOARD; AND

25 (2) PAY TO THE BOARD AN APPLICATION FEE, AS SET BY THE BOARD IN  
26 REGULATION.

27 (C) THE APPLICATION SHALL INCLUDE:

28 (1) THE NAME, FULL BUSINESS ADDRESS, AND TELEPHONE NUMBER OF  
29 THE APPLICANT;

30 (2) ALL TRADE OR BUSINESS NAMES USED BY THE APPLICANT;

31 (3) ADDRESSES, TELEPHONE NUMBERS, AND THE NAMES OF  
32 DESIGNATED REPRESENTATIVES FOR ALL FACILITIES USED BY THE APPLICANT FOR  
33 THE STORAGE, HANDLING, AND DISTRIBUTION OF PRESCRIPTION DRUGS;

34 (4) THE TYPE OF OWNERSHIP OR OPERATION OF THE APPLICANT;

1 (5) THE NAMES OF THE OWNER AND OPERATOR OF THE APPLICANT,  
2 INCLUDING:

3 (I) IF AN INDIVIDUAL, THE NAME OF THE INDIVIDUAL;

4 (II) IF A PARTNERSHIP, THE NAME OF EACH PARTNER, AND THE  
5 NAME OF THE PARTNERSHIP;

6 (III) IF A CORPORATION, THE NAME AND TITLE OF EACH  
7 CORPORATE OFFICER AND DIRECTOR, THE CORPORATE NAMES, AND THE STATE OF  
8 INCORPORATION; AND

9 (IV) IF A SOLE PROPRIETORSHIP, THE FULL NAME OF THE SOLE  
10 PROPRIETOR AND THE NAME OF THE BUSINESS ENTITY; AND

11 (6) A LIST OF ALL LICENSES AND PERMITS ISSUED TO THE APPLICANT  
12 BY ANY OTHER STATE THAT AUTHORIZES THE APPLICANT TO MANUFACTURE  
13 PRESCRIPTION DRUGS.

14 (D) THE INFORMATION REQUIRED UNDER THIS SECTION SHALL BE  
15 CERTIFIED BY A NOTARY PUBLIC.

16 (E) (1) THE BOARD SHALL ISSUE A MANUFACTURER LICENSE TO ANY  
17 APPLICANT THAT MEETS THE REQUIREMENTS OF THIS SECTION.

18 (2) IF THE BOARD DENIES A WHOLESALE DISTRIBUTOR LICENSE TO AN  
19 APPLICANT, IT SHALL GIVE THE APPLICANT WRITTEN NOTICE OF ITS DECISION AND  
20 THE REASONS FOR THE DENIAL.

21 (F) (1) A MANUFACTURER LICENSE SHALL BE VALID FOR A PERIOD OF 1  
22 YEAR.

23 (2) A LICENSE EXPIRES ON A DATE SET BY THE BOARD, UNLESS THE  
24 LICENSE IS RENEWED FOR AN ADDITIONAL 1-YEAR PERIOD AS PROVIDED IN THIS  
25 SUBSECTION.

26 (3) AT LEAST 1 MONTH BEFORE THE LICENSE EXPIRES, THE BOARD  
27 SHALL PROVIDE TO THE LICENSEE A RENEWAL NOTICE THAT STATES:

28 (I) THE DATE ON WHICH THE CURRENT LICENSE EXPIRES;

29 (II) THE DATE BY WHICH THE RENEWAL APPLICATION MUST BE  
30 RECEIVED BY THE BOARD FOR THE RENEWAL TO BE PROCESSED BEFORE THE  
31 LICENSE EXPIRES; AND

32 (III) THE AMOUNT OF THE RENEWAL FEE.

33 (4) BEFORE THE LICENSE EXPIRES, THE LICENSEE MAY RENEW THE  
34 LICENSE FOR AN ADDITIONAL 1-YEAR PERIOD, IF THE LICENSEE SUBMITS TO THE  
35 BOARD:

1 (I) A RENEWAL APPLICATION ON THE FORM THE BOARD  
2 REQUIRES; AND

3 (II) PAYS TO THE BOARD A RENEWAL FEE SET BY THE BOARD.

4 12-6B-13.

5 INFORMATION PROVIDED UNDER THIS SUBTITLE MAY NOT BE DISCLOSED TO  
6 ANY INDIVIDUAL OR ENTITY EXCEPT:

7 (1) THE BOARD OR OTHER STATE OR FEDERAL REGULATORY OR LAW  
8 ENFORCEMENT AGENCY; AND

9 (2) FOR A LAWFUL PURPOSE.

10 12-6B-14.

11 (A) THE BOARD SHALL ADOPT REGULATIONS DEFINING AN EMERGENCY  
12 SITUATION THAT WOULD PERMIT AN IMMEDIATE TRANSFER, WITHOUT PEDIGREE  
13 INFORMATION, OF PRESCRIPTION DRUGS BETWEEN ENTITIES LICENSED BY THE  
14 BOARD.

15 (B) THE REGULATIONS SHALL REQUIRE NOTIFICATION OF THE IMMEDIATE  
16 TRANSFER TO THE BOARD WITH 24 HOURS OF THE TRANSFER.

17 (C) THE BOARD SHALL DETERMINE WHETHER THE IMMEDIATE TRANSFER  
18 MEETS THE DEFINITION OF AN EMERGENCY SITUATION.

19 (D) IF THE BOARD DETERMINES THAT THE IMMEDIATE TRANSFER DOES NOT  
20 MEET THE DEFINITION OF AN EMERGENCY SITUATION, THE BOARD MAY TAKE  
21 ACTION UNDER § 12-6B-11 OR § 12-6B-20 OF THIS SUBTITLE.

22 12-6B-15.

23 (A) A WHOLESALE DISTRIBUTOR SHALL RECEIVE PRESCRIPTION DRUG  
24 RETURNS OR EXCHANGES FROM A PHARMACY OR CHAIN PHARMACY WAREHOUSE IN  
25 ACCORDANCE WITH THE TERMS AND CONDITIONS OF THE AGREEMENT BETWEEN  
26 THE WHOLESALE DISTRIBUTOR AND THE PHARMACY OR CHAIN PHARMACY  
27 WAREHOUSE.

28 (B) RETURNS MAY INCLUDE EXPIRED, DAMAGED, OR RECALLED  
29 PRESCRIPTION DRUGS BEING RETURNED TO EITHER THE ORIGINAL MANUFACTURER  
30 OR A THIRD PARTY RETURNS PROCESSOR.

31 (C) RETURNS OR EXCHANGES ARE NOT SUBJECT TO THE REQUIREMENTS OF  
32 § 12-6B-17 OF THIS SUBTITLE.

33 (D) THE BOARD SHALL REQUIRE WHOLESALE DISTRIBUTORS TO:

34 (1) POLICE AND MAINTAIN THE SECURITY OF THEIR RETURNS PROCESS;  
35 AND

1 (2) PREVENT THE ENTRY OF ADULTERATED OR COUNTERFEIT  
2 PRESCRIPTION DRUGS INTO THE PRESCRIPTION DRUG DISTRIBUTION SYSTEM.

3 12-6B-16.

4 (A) (1) BEFORE THE INITIAL PURCHASE OR SALE OF PRESCRIPTION DRUGS  
5 TO OR FROM A WHOLESALE DISTRIBUTOR, THE WHOLESALE DISTRIBUTOR SHALL  
6 ADHERE TO THE DUE DILIGENCE REQUIREMENTS AND STANDARDS SET BY THE  
7 BOARD.

8 (2) THE BOARD MAY WAIVE THE DUE DILIGENCE REQUIREMENTS IF  
9 THE INFORMATION HAS BEEN VERIFIED BY A THIRD PARTY WORKING ON BEHALF OF  
10 THE BOARD.

11 (B) A WHOLESALE DISTRIBUTOR:

12 (1) MAY SUPPLY PRESCRIPTION DRUGS ONLY TO A RECIPIENT  
13 LICENSED BY THE BOARD; AND

14 (2) SHALL CONTACT THE BOARD TO VERIFY THE AUTHENTICITY OF THE  
15 LICENSE.

16 (C) (1) EXCEPT AS PROVIDED IN PARAGRAPH (2) OF THIS SUBSECTION, A  
17 WHOLESALE DISTRIBUTOR MAY DELIVER PRESCRIPTION DRUGS ONLY TO:

18 (I) THE PREMISES LISTED ON THE RECIPIENT'S LICENSE; OR

19 (II) AN AUTHORIZED AGENT OF THE RECIPIENT AT THE PREMISES  
20 OF THE WHOLESALE DISTRIBUTOR IF:

21 1. THE IDENTITY AND AUTHORIZATION OF THE  
22 AUTHORIZED AGENT IS PROPERLY ESTABLISHED; AND

23 2. THIS METHOD OF RECEIPT IS EMPLOYED ONLY TO MEET  
24 THE IMMEDIATE NEEDS OF A PARTICULAR PATIENT.

25 (2) (I) PRESCRIPTION DRUGS MAY BE SUPPLIED TO A HOSPITAL  
26 PHARMACY RECEIVING AREA PROVIDED THAT A PHARMACIST OR AUTHORIZED  
27 RECEIVING PERSONNEL OF THE HOSPITAL PHARMACY SIGNS, AT THE TIME OF  
28 DELIVERY, A RECEIPT INDICATING THE TYPE AND QUANTITY OF THE PRESCRIPTION  
29 DRUG RECEIVED.

30 (II) ANY DISCREPANCY BETWEEN THE TYPE AND QUANTITY OF  
31 THE PRESCRIPTION DRUG INDICATED ON THE RECEIPT AND THE TYPE AND  
32 QUANTITY OF THE PRESCRIPTION DRUG ACTUALLY RECEIVED SHALL BE REPORTED  
33 TO THE DELIVERING WHOLESALE DISTRIBUTOR BY THE NEXT BUSINESS DAY AFTER  
34 THE DELIVERY TO THE HOSPITAL PHARMACY RECEIVING AREA.



1 (D) (1) EXCEPT AS PROVIDED IN PARAGRAPH (3) OF THIS SUBSECTION, ONLY  
2 THE OWNER OF RECORD, THE CHIEF EXECUTIVE OFFICER, OR THE CHIEF FINANCIAL  
3 OFFICER OF AN ENTITY LICENSED TO RECEIVE PRESCRIPTION DRUGS MAY:

4 (I) PROVIDE PAYMENT FOR PRESCRIPTION DRUGS TO A  
5 WHOLESALE DISTRIBUTOR; OR

6 (II) USE CREDIT TO ESTABLISH AN ACCOUNT WITH A WHOLESALE  
7 DISTRIBUTOR FOR THE PURCHASE OF PRESCRIPTION DRUGS.

8 (2) ANY ACCOUNT ESTABLISHED FOR THE PURCHASE OF PRESCRIPTION  
9 DRUGS MUST BEAR THE NAME OF THE LICENSEE.

10 (3) (I) NOTWITHSTANDING PARAGRAPH (1) OF THIS SUBSECTION,  
11 STANDARD ORDERING AND PURCHASING BUSINESS PRACTICES MAY OCCUR  
12 BETWEEN:

- 13 1. PHARMACIES;
- 14 2. CHAIN PHARMACY WAREHOUSES;
- 15 3. WHOLESALE DISTRIBUTORS; AND
- 16 4. MANUFACTURERS.

17 (II) STANDARD ORDERING AND PURCHASING BUSINESS PRACTICES  
18 INCLUDE PRACTICES IN WHICH:

- 19 1. PRESCRIPTION DRUGS ARE SHIPPED BY A  
20 MANUFACTURER OR MANUFACTURERS TO A PHARMACY OR CHAIN PHARMACY  
21 WAREHOUSE AND THE PAYMENT PROCESSED THROUGH A WHOLESALER;
- 22 2. A PHARMACY OR CHAIN PHARMACY WAREHOUSE ORDERS  
23 PRESCRIPTION DRUGS FROM ONE OR MORE DIFFERENT MANUFACTURERS AND THE  
24 ORDERS ARE AGGREGATED BY A WHOLESALER AND DELIVERED TO THE PHARMACY  
25 OR CHAIN PHARMACY WAREHOUSE IN THE SAME DELIVERY; OR
- 26 3. THE BOARD AUTHORIZES THE PRACTICE IN REGULATION.  
27 12-6B-17.

28 (A) (1) A WHOLESALE DISTRIBUTOR SHALL ESTABLISH AND MAINTAIN  
29 INVENTORIES AND RECORDS OF ALL TRANSACTIONS REGARDING THE RECEIPT AND  
30 DISTRIBUTION OR OTHER DISPOSITION OF PRESCRIPTION DRUGS.

31 (2) RECORDS SHALL INCLUDE PEDIGREES FOR WHOLESALE  
32 DISTRIBUTIONS OF ALL PRESCRIPTION DRUGS THAT OCCUR BOTH INSIDE AND  
33 OUTSIDE THE NORMAL DISTRIBUTION CHANNEL.

34 (B) A WHOLESALE DISTRIBUTOR OF A PRESCRIPTION DRUG, INCLUDING A  
35 REPACKAGER, BUT EXCLUDING THE ORIGINAL MANUFACTURER OF THE FINISHED

1 FORM OF THE PRESCRIPTION DRUG, THAT IS IN POSSESSION OF A PEDIGREE FOR A  
2 PRESCRIPTION DRUG AND ATTEMPTS TO FURTHER DISTRIBUTE THAT PRESCRIPTION  
3 DRUG, SHALL AFFIRMATIVELY VERIFY BEFORE ANY DISTRIBUTION OF A  
4 PRESCRIPTION DRUG OCCURS THAT EACH TRANSACTION LISTED ON THE PEDIGREE  
5 HAS OCCURRED.

6 (C) (1) THE PEDIGREE SHALL INCLUDE ALL NECESSARY IDENTIFYING  
7 INFORMATION CONCERNING EACH SALE IN THE CHAIN OF DISTRIBUTION OF THE  
8 PRESCRIPTION DRUG FROM THE MANUFACTURER, THROUGH ACQUISITION AND  
9 SALE BY EACH WHOLESALE DISTRIBUTOR OR REPACKAGER, UNTIL FINAL SALE TO A  
10 CHAIN PHARMACY WAREHOUSE, OR TO A PHARMACY OR OTHER PERSON DISPENSING  
11 OR ADMINISTERING THE DRUG.

12 (2) THE NECESSARY CHAIN OF DISTRIBUTION INFORMATION SHALL  
13 INCLUDE:

14 (I) NAME, ADDRESS, TELEPHONE NUMBER, AND IF AVAILABLE,  
15 THE ELECTRONIC MAIL ADDRESS, OF EACH OWNER AND EACH WHOLESALE  
16 DISTRIBUTOR OF THE PRESCRIPTION DRUG;

17 (II) NAME AND ADDRESS OF EACH LOCATION FROM WHICH THE  
18 PRODUCT WAS SHIPPED, IF DIFFERENT FROM THE OWNER'S;

19 (III) TRANSACTION DATES; AND

20 (IV) CERTIFICATION THAT EACH RECIPIENT HAS AUTHENTICATED  
21 THE PEDIGREE.

22 (3) THE PEDIGREE SHALL ALSO INCLUDE:

23 (I) THE NAME OF THE PRESCRIPTION DRUG;

24 (II) DOSAGE FORM AND STRENGTH OF THE PRESCRIPTION DRUG;

25 (III) SIZE OF THE CONTAINER;

26 (IV) NUMBER OF CONTAINERS;

27 (V) LOT NUMBER OF THE PRESCRIPTION DRUG; AND

28 (VI) NAME OF THE MANUFACTURER OF THE FINISHED DOSAGE  
29 FORM.

30 (D) EACH PEDIGREE SHALL BE:

31 (1) MAINTAINED BY THE PURCHASER AND THE WHOLESALE  
32 DISTRIBUTOR FOR 3 YEARS FROM THE DATE OF SALE OR TRANSFER; AND

33 (2) AVAILABLE FOR INSPECTION OR USE WITHIN 2 CALENDAR DAYS ON  
34 A REQUEST OF AN AUTHORIZED OFFICER OF THE LAW.

1 (E) (1) THE BOARD SHALL CONDUCT A STUDY OF ELECTRONIC PEDIGREES  
2 AND OTHER ADVANCED TECHNOLOGY FOR TRACKING PRESCRIPTION DRUGS.

3 (2) THE STUDY SHALL BE CONDUCTED IN CONSULTATION WITH  
4 PARTICIPANTS CHOSEN BY THE BOARD.

5 (3) BASED ON THE STUDY, THE BOARD MAY MANDATE ELECTRONIC  
6 PEDIGREES OR OTHER ADVANCED TRACKING TECHNOLOGY.

7 (4) THE IMPLEMENTATION DATE FOR ANY MANDATED ELECTRONIC  
8 PEDIGREE OR OTHER ADVANCED TRACKING TECHNOLOGY SHALL BE NO SOONER  
9 THAN DECEMBER 31, 2007.

10 (5) THE BOARD SHALL REPORT THE FINDINGS AND RECOMMENDATIONS  
11 OF ITS STUDY TO THE GOVERNOR AND, IN ACCORDANCE WITH § 2-1246 OF THE STATE  
12 GOVERNMENT ARTICLE, THE GENERAL ASSEMBLY, ON OR BEFORE JANUARY 1, 2007.

13 (6) THE BOARD SHALL ADOPT REGULATIONS RELATING TO MANDATED  
14 ELECTRONIC PEDIGREES OR OTHER ADVANCED TRACKING TECHNOLOGY AT LEAST  
15 180 DAYS PRIOR TO THE IMPLEMENTATION DATE.

16 (F) THE BOARD SHALL EXEMPT A PHARMACY BENEFITS ENTITY FROM THIS  
17 SECTION, IF:

18 (1) THE PHARMACY BENEFITS ENTITY'S PURCHASES ARE SOLELY FROM  
19 A MANUFACTURER OR A WHOLESALE DISTRIBUTOR IN THE NORMAL DISTRIBUTION  
20 CHANNEL; AND

21 (2) ANY SUBSEQUENT SALE OR FURTHER DISTRIBUTIONS ARE:

22 (I) WITHIN THE NORMAL DISTRIBUTION CHANNEL;

23 (II) TO A HOSPITAL; OR

24 (III) TO A PHYSICIAN.

25 (G) A DISTRIBUTION FROM A PHARMACY BENEFITS ENTITY TO A WHOLESALE  
26 DISTRIBUTOR IS SUBJECT TO THE REQUIREMENTS OF SUBSECTIONS (A) THROUGH  
27 (D) OF THIS SECTION.

28 (H) THE BOARD MAY RECOGNIZE THE LAWS AND REGULATIONS OF OTHER  
29 STATES AND U.S. TERRITORIES PERTAINING TO PRESCRIPTION DRUG PEDIGREE  
30 REQUIREMENTS AS SATISFYING THE PEDIGREE REQUIREMENTS OF THIS SECTION.

31 12-6B-18.

32 (A) THE BOARD SHALL ISSUE AN ORDER REQUIRING THE APPROPRIATE  
33 PERSON, INCLUDING THE WHOLESALE DISTRIBUTOR OR RETAILER OF A  
34 PRESCRIPTION DRUG, TO IMMEDIATELY CEASE DISTRIBUTION OF THE DRUG IF THE  
35 BOARD FINDS A REASONABLE PROBABILITY THAT:

- 1 (1) A WHOLESALE DISTRIBUTOR HAS:
- 2 (I) VIOLATED A PROVISION IN THIS SUBTITLE;
- 3 (II) FALSIFIED A PEDIGREE; OR
- 4 (III) SOLD, DISTRIBUTED, TRANSFERRED, MANUFACTURED,  
5 REPACKAGED, HANDLED, OR HELD A COUNTERFEIT PRESCRIPTION DRUG INTENDED  
6 FOR HUMAN USE;
- 7 (2) THE PRESCRIPTION DRUG AT ISSUE AS A RESULT OF A VIOLATION IN  
8 PARAGRAPH (1) OF THIS SUBSECTION COULD CAUSE SERIOUS, ADVERSE HEALTH  
9 CONSEQUENCES OR DEATH; AND
- 10 (3) OTHER PROCEDURES WOULD RESULT IN UNREASONABLE DELAY.
- 11 (B) (1) AN ORDER UNDER SUBSECTION (A) OF THIS SECTION SHALL  
12 PROVIDE THE PERSON SUBJECT TO THE ORDER WITH AN OPPORTUNITY FOR AN  
13 INFORMAL HEARING BEFORE THE BOARD, TO BE HELD NOT LATER THAN 10 DAYS  
14 AFTER THE DATE OF THE ISSUANCE OF THE ORDER, ON THE ACTIONS REQUIRED BY  
15 THE ORDER.
- 16 (2) IF, AFTER PROVIDING AN OPPORTUNITY FOR A HEARING, THE BOARD  
17 DETERMINES THAT INADEQUATE GROUNDS EXIST TO SUPPORT THE ACTIONS  
18 REQUIRED BY THE ORDER, THE BOARD SHALL VACATE THE ORDER.
- 19 12-6B-19.
- 20 (A) A PERSON MAY NOT PERFORM OR CAUSE THE PERFORMANCE OF OR AID  
21 AND ABET ANY OF THE FOLLOWING ACTS:
- 22 (1) (I) FAILURE TO OBTAIN A LICENSE IN ACCORDANCE WITH THIS  
23 SUBTITLE; OR
- 24 (II) OPERATING WITHOUT A VALID LICENSE WHEN A LICENSE IS  
25 REQUIRED BY THIS SUBTITLE;
- 26 (2) THE SALE, DISTRIBUTION, OR TRANSFER OF A PRESCRIPTION DRUG  
27 TO A PERSON THAT IS NOT AUTHORIZED BY LAW TO RECEIVE THE PRESCRIPTION  
28 DRUG, IN VIOLATION OF § 12-6B-16(B) OF THIS SUBTITLE;
- 29 (3) FAILURE TO DELIVER PRESCRIPTION DRUGS TO SPECIFIED  
30 PREMISES, AS REQUIRED UNDER § 12-6B-16(C) OF THIS SUBTITLE;
- 31 (4) ACCEPTING PAYMENT OR CREDIT FOR THE SALE OF PRESCRIPTION  
32 DRUGS IN VIOLATION OF § 12-6B-16(D) OF THIS SUBTITLE;
- 33 (5) FAILURE TO MAINTAIN OR PROVIDE PEDIGREES AS REQUIRED  
34 UNDER THIS SUBTITLE;

1 (6) FAILURE TO OBTAIN, PASS, OR AUTHENTICATE A PEDIGREE, AS  
2 REQUIRED UNDER THIS SUBTITLE;

3 (7) FAILURE TO PROVIDE INFORMATION TO A PURCHASER OR SELLER  
4 OF PRESCRIPTION DRUGS THAT IS NECESSARY TO CREATE, OBTAIN, PASS, OR  
5 AUTHENTICATE A PEDIGREE;

6 (8) PROVIDING THE BOARD OR ANY OF ITS REPRESENTATIVES OR ANY  
7 FEDERAL OFFICIAL WITH FALSE OR FRAUDULENT RECORDS OR MAKING FALSE OR  
8 FRAUDULENT STATEMENTS REGARDING ANY MATTER WITHIN THE PROVISIONS OF  
9 THIS SUBTITLE;

10 (9) OBTAINING OR ATTEMPTING TO OBTAIN A PRESCRIPTION DRUG BY  
11 FRAUD, DECEIT, MISREPRESENTATION, OR ENGAGING IN MISREPRESENTATION OR  
12 FRAUD IN THE WHOLESALE DISTRIBUTION OF A PRESCRIPTION DRUG;

13 (10) EXCEPT FOR THE WHOLESALE DISTRIBUTION BY MANUFACTURERS  
14 OF A PRESCRIPTION DRUG THAT HAS BEEN DELIVERED INTO COMMERCE PURSUANT  
15 TO AN APPLICATION APPROVED UNDER FEDERAL LAW BY THE U.S. FOOD AND DRUG  
16 ADMINISTRATION, THE MANUFACTURE, REPACKAGING, SALE, TRANSFER, DELIVERY,  
17 HOLDING, OR OFFERING FOR SALE OF ANY PRESCRIPTION DRUG THAT IS:

18 (I) ADULTERATED;

19 (II) MISBRANDED;

20 (III) COUNTERFEIT;

21 (IV) SUSPECTED OF BEING COUNTERFEIT; OR

22 (V) OTHERWISE RENDERED UNFIT FOR DISTRIBUTION;

23 (11) EXCEPT FOR THE WHOLESALE DISTRIBUTION BY MANUFACTURERS  
24 OF A PRESCRIPTION DRUG THAT HAS BEEN DELIVERED INTO COMMERCE PURSUANT  
25 TO AN APPLICATION APPROVED UNDER FEDERAL LAW BY THE FOOD AND DRUG  
26 ADMINISTRATION, THE ADULTERATION, MISBRANDING, OR COUNTERFEITING OF  
27 ANY PRESCRIPTION DRUG;

28 (12) (I) THE RECEIPT OF ANY PRESCRIPTION DRUG WITH KNOWLEDGE  
29 THAT THE DRUG IS ADULTERATED, MISBRANDED, STOLEN, OBTAINED BY FRAUD OR  
30 DECEIT, COUNTERFEIT, OR SUSPECTED OF BEING COUNTERFEIT; OR

31 (II) THE DELIVERY OR PROFFERED DELIVERY OF SUCH DRUG FOR  
32 PAY OR OTHERWISE; OR

33 (13) (I) THE ALTERATION, MUTILATION, DESTRUCTION,  
34 OBLITERATION, OR REMOVAL OF THE WHOLE OR ANY PART OF THE LABELING OF A  
35 PRESCRIPTION DRUG; OR

1 (II) THE COMMISSION OF ANY OTHER ACT WITH RESPECT TO A  
2 PRESCRIPTION DRUG THAT RESULTS IN THE PRESCRIPTION DRUG BEING  
3 MISBRANDED.

4 (B) IT IS NOT UNLAWFUL FOR A PRESCRIPTION DRUG MANUFACTURER OR  
5 AGENT OF A PRESCRIPTION DRUG MANUFACTURER TO OBTAIN OR ATTEMPT TO  
6 OBTAIN A PRESCRIPTION DRUG FOR THE SOLE PURPOSE OF TESTING THE  
7 PRESCRIPTION DRUG FOR AUTHENTICITY.

8 12-6B-20.

9 A PERSON WHO VIOLATES ANY PROVISION OF THIS SUBTITLE IS GUILTY OF A  
10 FELONY AND ON CONVICTION IS SUBJECT TO A FINE NOT TO EXCEED \$500,000 OR  
11 IMPRISONMENT NOT TO EXCEED 25 YEARS OR BOTH.

12 12-707.

13 (b) A person who violates any provision of the following sections of this title is  
14 guilty of a misdemeanor and on conviction is subject to a fine not exceeding \$1,000 or  
15 imprisonment not exceeding 1 year or both:

16 [(1) § 12-602 ("Distribution permits");]

17 [(2)] (1) § 12-701 ("Practicing pharmacy without license");

18 [(3)] (2) § 12-702 ("License obtained by false representation");

19 [(4)] (3) § 12-703 ("Operating a pharmacy without permit"); and

20 [(5)] (4) § 12-704 ("Misrepresentations").

21 SECTION 3. AND BE IT FURTHER ENACTED, That this Act shall take effect  
22 October 1, 2006.